SCHEMBL10119756

SCHEMBL10119756

COc1ccc(CNc2cc(-c3ccccc3)no2)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
LMNA P02545 4/20 0.56
KDM4E B2RXH2 4/20 0.56
ALDH1A1 P00352 4/20 0.56
TDP1 Q9NUW8 3/20 0.56
KMT2A Q03164 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
HPGD P15428 2/20 0.56
SMN1; SMN2 Q16637 6/20 0.53
MEN1 O00255 1/20 0.52
POLB P06746 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
HSD17B10 Q99714 1/20 0.50
TP53 P04637 1/20 0.48
APP P05067 1/20 0.47
BCHE P06276 3/20 0.47
ACHE P22303 3/20 0.47
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10119758 0.80 NPC1 (0.54) MAPTKMT2ASMN1; SMN2MEN1POLB
SCHEMBL14265513 0.75 SMN1; SMN2 (0.47) MAPTLMNAKDM4EALDH1A1TDP1
SCHEMBL10119775 0.74 MAPT (0.74) MAPTLMNAKDM4EALDH1A1TDP1
SCHEMBL10119764 0.74 KDM4E (0.55) MAPTLMNAKDM4EALDH1A1TDP1
SCHEMBL4861526 0.73 MAPT (0.74) MAPTLMNAKDM4EALDH1A1TDP1
SCHEMBL633356 0.73 CA12 (0.59) MAPTLMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL10119743 0.72 MAPT (0.71) MAPTLMNAKDM4EALDH1A1TDP1
SCHEMBL10119723 0.71 MAPT (0.57) MAPTLMNAKDM4EALDH1A1TDP1
SCHEMBL10119769 0.71 MAPT (0.64) MAPTLMNAKDM4EALDH1A1TDP1
SCHEMBL10119750 0.70 KMT2A (0.56) MAPTLMNAKDM4EALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8466182-B2 Small molecule inhibitors of kynurenine-3-monooxygenase THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) 2013-06-18 US disclosed
US-20120046324-A1 SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046324-A1 SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE KMO, KYNU, TDO2 MAPT 680/4885LMNA 4391/4885KDM4E 1039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.